Facebook
Twitter
LinkedIn
Forward
(CE/CME Podcast) Improving Outcomes in Patients With Geographic Atrophy: Treatment and Referral
Activity Description and Purpose
This educational activity explores the advancements in geographic atrophy (GA) treatment options, focusing on clinical science data and real-world clinical presentations. Participants will gain insights into the latest US Food and Drug Administration–approved treatments, their mechanisms of action, clinical trial results, and patient safety considerations. Additionally, the educational activity emphasizes application in clinical practice via case examples, effective patient counseling techniques, and referral strategies to enhance patient outcomes and quality of life. This CME/CE activity is designed to enhance clinical competence and improve patient care in the management of GA. The desired results of this educational activity are for optometrists and comprehensive ophthalmologists to enhance their knowledge of new treatment options and to improve their competence in managing patients with GA.
Target Audience
This educational activity is intended for optometrists and comprehensive ophthalmologists.
Learning Objectives
After completing this activity, participants will be better able to:
- Review clinical data for complement inhibitors used in the treatment of geographic atrophy
- Develop appropriate treatment plans for patients with geographic atrophy
- Employ appropriate counseling techniques for patients with geographic atrophy to facilitate referral
You may also be interested in
Faculty
 | David Eichenbaum, MD |
 | Mary Beth Yackey, OD Cincinnati Eye Institute Blue Ash, Ohio Edgewood, Kentucky |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
David Eichenbaum, MD, is a consultant for AbbVie Inc, Alimera Sciences, Annexon Inc, Apellis Pharmaceuticals, Astellas Pharma Inc, Bausch & Lomb Incorporated, Coherus BioSciences, EyePoint Pharmaceuticals, Genentech, Inc, Iveric Bio, Inc, Kodiak Sciences Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Ocuphire Pharma, Opthea, Outlook Therapeutics, Inc, Recens Medical, Inc, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, ReVive Biotechnology, and Samsara Vision, Inc; is on the speakers bureau for AbbVie Inc, Apellis Pharmaceuticals, Astellas Pharma Inc, Genentech, Inc, Iveric Bio, Inc, and Regeneron Pharmaceuticals, Inc; is a contracted researcher for Aerie Pharmaceuticals, Inc, Alexion Pharmaceuticals, Inc, Allegenesis Biotherapeutics Inc, Annexon Inc, Astellas Pharma Inc, Aviceda Therapeutics, Bayer Corporation, EyePoint Pharmaceuticals, 4DMT, Gemini Therapeutics, Genentech, Inc, Gyroscope, Ionis Pharmaceuticals, Inc, Iveric Bio, Inc, Janssen Pharmaceuticals, Inc, Kodiak Sciences Inc, NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Opthea, ONL Therapeutics, Recens Medical, Inc, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Unity Biotechnology, and Viatris Inc; and has stock options in ReVive Biotechnology.
Mary Beth Yackey, OD, is a consultant for Apellis Pharmaceuticals, Astellas Pharma Inc, Haag-Streit Group, Iveric Bio, Inc, and Notal Vision; is an advisory board member of Apellis Pharmaceuticals, Astellas Pharma Inc, Haag-Streit Group, Iveric Bio, Inc, Novartis Pharmaceuticals Corporation, and OcuTerra Therapeutics; is on the speakers bureau for Astellas Pharma Inc and Iveric Bio, Inc; and is a contracted researcher for Notal Vision.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Medical Writer: Robert M. Geist IV, MD, is a consultant for Ascendis Pharma Group; and formerly a paid employee of Fresenius Medical Care.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
COPE approved for 0.5 CE credit for optometrists.
COPE Course ID: 92100-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease
Administrator: 
This activity, COPE Activity Number 128764, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus has received commercial support from Astellas Pharma Inc for this activity in the form of an unrestricted educational grant.
The content of this ACCME-/COPE-accredited CME/CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Sponsored by 
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, State University of New York College of Optometry, or Astellas Pharma Inc.
This CME/CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 318.1BP
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 COPE
- 0.50 Participation